Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.01 per share a year ago.

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved ...

Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.